Long	Long	JJ	B-NP	O		0	4
-	-	HYPH	I-NP	O		4	5
term	term	NN	I-NP	O		5	9
Helicobacter pylori	Helicobacter_pylori	NN	I-NP	O		10	29
infection	infection	NN	I-NP	O		30	39
and	and	CC	O	O		40	43
the	the	DT	B-NP	O		44	47
development	development	NN	I-NP	O		48	59
of	of	IN	B-PP	O		60	62
atrophic	atrophic	JJ	B-NP	O		63	71
gastritis	gastritis	NN	I-NP	O		72	81
and	and	CC	O	O		82	85
gastric	gastric	JJ	B-NP	O		86	93
cancer	cancer	NN	I-NP	O		94	100
in	in	IN	B-PP	O		101	103
Japan	Japan	NNP	B-NP	O		104	109
.	.	.	O	O		109	110

The	The	DT	B-NP	O		111	114
incidence	incidence	NN	I-NP	O		115	124
of	of	IN	B-PP	O		125	127
gastric	gastric	JJ	B-NP	O		128	135
cancer	cancer	NN	I-NP	O		136	142
and	and	CC	O	O		143	146
the	the	DT	B-NP	O		147	150
prevalence	prevalence	NN	I-NP	O		151	161
of	of	IN	B-PP	O		162	164
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O		165	184
are	be	VBP	B-VP	O		185	188
high	high	JJ	B-ADJP	O		189	193
in	in	IN	B-PP	O		194	196
Japan	Japan	NNP	B-NP	O		197	202
,	,	,	O	O		202	203
so	so	IN	B-SBAR	O		204	206
it	it	PRP	B-NP	O		207	209
is	be	VBZ	B-VP	O		210	212
an	an	DT	B-NP	O		213	215
important	important	JJ	I-NP	O		216	225
issue	issue	NN	I-NP	O		226	231
whether	whether	IN	B-SBAR	O		232	239
long	long	JJ	B-NP	O		240	244
-	-	HYPH	I-NP	O		244	245
term	term	NN	I-NP	O		245	249
H. pylori	H._pylori	NN	I-NP	O		250	259
infection	infection	NN	I-NP	O		260	269
leads	lead	VBZ	B-VP	O		270	275
to	to	TO	B-PP	O		276	278
chronic	chronic	JJ	B-NP	O		279	286
atrophic	atrophic	JJ	I-NP	O		287	295
gastritis	gastritis	NN	I-NP	O		296	305
,	,	,	O	O		305	306
considered	consider	VBD	B-VP	O		307	317
one	one	CD	B-NP	O		318	321
of	of	IN	B-PP	O		322	324
the	the	DT	B-NP	O		325	328
precursors	precursor	NNS	I-NP	O		329	339
of	of	IN	B-PP	O		340	342
gastric	gastric	JJ	B-NP	O		343	350
cancer	cancer	NN	I-NP	O		351	357
.	.	.	O	O		357	358

We	We	PRP	B-NP	O		359	361
have	have	VBP	B-VP	O		362	366
reported	report	VBN	I-VP	O		367	375
that	that	IN	B-SBAR	O		376	380
the	the	DT	B-NP	O		381	384
grade	grade	NN	I-NP	O		385	390
of	of	IN	B-PP	O		391	393
atrophy	atrophy	NN	B-NP	O		394	401
was	be	VBD	B-VP	O		402	405
higher	high	JJR	B-ADJP	O		406	412
in	in	IN	B-PP	O		413	415
H. pylori	H._pylori	NNP	B-NP	O		416	425
-	-	HYPH	I-NP	O		425	426
positive	positive	JJ	I-NP	O		426	434
subjects	subject	NNS	I-NP	O		435	443
than	than	IN	B-PP	O		444	448
in	in	IN	B-PP	O		449	451
H. pylori	H._pylori	NN	B-NP	O		452	461
-	-	HYPH	B-NP	O		461	462
negative	negative	JJ	I-NP	O		462	470
subjects	subject	NNS	I-NP	O		471	479
.	.	.	O	O		479	480

It	It	PRP	B-NP	O		481	483
has	have	VBZ	B-VP	O		484	487
also	also	RB	I-VP	O		488	492
been	be	VBN	I-VP	O		493	497
reported	report	VBN	I-VP	O		498	506
that	that	IN	B-SBAR	O		507	511
the	the	DT	B-NP	O		512	515
atrophy	atrophy	NN	I-NP	O		516	523
of	of	IN	B-PP	O		524	526
gastric	gastric	JJ	B-NP	O		527	534
mucosa	mucosa	NN	I-NP	O		535	541
increased	increase	VBD	B-VP	O		542	551
in	in	IN	B-PP	O		552	554
H. pylori	H._pylori	NN	B-NP	O		555	564
-	-	HYPH	B-NP	O		564	565
infected	infect	VBN	I-NP	O		565	573
monkeys	monkey	NNS	I-NP	O		574	581
compared	compare	VBN	B-PP	O		582	590
with	with	IN	B-PP	O		591	595
control	control	NN	B-NP	O		596	603
monkeys	monkey	NNS	I-NP	O		604	611
in	in	IN	B-PP	O		612	614
a	a	DT	B-NP	O		615	616
5-year	5-year	JJ	I-NP	O		617	623
follow-up	follow-up	JJ	I-NP	O		624	633
study	study	NN	I-NP	O		634	639
.	.	.	O	O		639	640

Most	Most	JJS	B-NP	O		641	645
H. pylori	H._pylori	NNP	I-NP	O		646	655
infections	infection	NNS	I-NP	O		656	666
occur	occur	VBP	B-VP	O		667	672
in	in	IN	B-PP	O		673	675
children	child	NNS	B-NP	O		676	684
,	,	,	O	O		684	685
and	and	CC	O	O		686	689
atrophy	atrophy	NN	B-NP	O		690	697
of	of	IN	B-PP	O		698	700
the	the	DT	B-NP	O		701	704
gastric	gastric	JJ	I-NP	O		705	712
mucosa	mucosa	NN	I-NP	O		713	719
progresses	progress	NNS	I-NP	O		720	730
during	during	IN	B-PP	O		731	737
aging	aging	NN	B-NP	O		738	743
.	.	.	O	O		743	744

Long	Long	JJ	B-NP	O		745	749
-	-	HYPH	I-NP	O		749	750
term	term	NN	I-NP	O		750	754
data	datum	NNS	I-NP	O		755	759
show	show	VBP	B-VP	O		760	764
that	that	IN	B-SBAR	O		765	769
H. pylori	H._pylori	NN	B-NP	O		770	779
infection	infection	NN	I-NP	O		780	789
can	can	MD	B-VP	O		790	793
lead	lead	VB	I-VP	O		794	798
to	to	TO	B-PP	O		799	801
gastric	gastric	JJ	B-NP	O		802	809
atrophy	atrophy	NN	I-NP	O		810	817
and	and	CC	O	O		818	821
may	may	MD	B-VP	O		822	825
play	play	VB	I-VP	O		826	830
an	an	DT	B-NP	O		831	833
important	important	JJ	I-NP	O		834	843
role	role	NN	I-NP	O		844	848
in	in	IN	B-PP	O		849	851
the	the	DT	B-NP	O		852	855
development	development	NN	I-NP	O		856	867
of	of	IN	B-PP	O		868	870
gastric	gastric	JJ	B-NP	O		871	878
cancer	cancer	NN	I-NP	O		879	885
.	.	.	O	O		885	886

Interestingly	Interestingly	RB	B-ADVP	O		887	900
,	,	,	O	O		900	901
there	there	EX	B-NP	O		902	907
was	be	VBD	B-VP	O		908	911
no	no	DT	B-NP	O		912	914
difference	difference	NN	I-NP	O		915	925
in	in	IN	B-PP	O		926	928
the	the	DT	B-NP	O		929	932
prevalence	prevalence	NN	I-NP	O		933	943
of	of	IN	B-PP	O		944	946
H. pylori	H._pylori	NN	B-NP	O		947	956
between	between	IN	B-PP	O		957	964
patients	patient	NNS	B-NP	O		965	973
with	with	IN	B-PP	O		974	978
chronic	chronic	JJ	B-NP	O		979	986
gastritis	gastritis	NN	I-NP	O		987	996
and	and	CC	O	O		997	1000
gastric	gastric	JJ	B-NP	O		1001	1008
cancer	cancer	NN	I-NP	O		1009	1015
in	in	IN	B-PP	O		1016	1018
Japan	Japan	NNP	B-NP	O		1019	1024
,	,	,	O	O		1024	1025
but	but	CC	O	O		1026	1029
the	the	DT	B-NP	O		1030	1033
prevalence	prevalence	NN	I-NP	O		1034	1044
of	of	IN	B-PP	O		1045	1047
H. pylori	H._pylori	NN	B-NP	O		1048	1057
in	in	IN	B-PP	O		1058	1060
young	young	JJ	B-NP	O		1061	1066
Japanese	Japanese	JJ	I-NP	O		1067	1075
gastric	gastric	JJ	I-NP	O		1076	1083
cancer	cancer	NN	I-NP	O		1084	1090
patients	patient	NNS	I-NP	O		1091	1099
was	be	VBD	B-VP	O		1100	1103
significantly	significantly	RB	B-ADJP	O		1104	1117
higher	high	JJR	I-ADJP	O		1118	1124
than	than	IN	B-PP	O		1125	1129
in	in	IN	B-PP	O		1130	1132
the	the	DT	B-NP	O		1133	1136
control	control	NN	I-NP	O		1137	1144
group	group	NN	I-NP	O		1145	1150
.	.	.	O	O		1150	1151

These	These	DT	B-NP	O		1152	1157
data	datum	NNS	I-NP	O		1158	1162
clearly	clearly	RB	B-VP	O		1163	1170
show	show	VBP	I-VP	O		1171	1175
that	that	IN	B-SBAR	O		1176	1180
H. pylori	H._pylori	NN	B-NP	O		1181	1190
infection	infection	NN	I-NP	O		1191	1200
is	be	VBZ	B-VP	O		1201	1203
one	one	CD	B-NP	O		1204	1207
of	of	IN	B-PP	O		1208	1210
the	the	DT	B-NP	O		1211	1214
risk	risk	NN	I-NP	O		1215	1219
factors	factor	NNS	I-NP	O		1220	1227
of	of	IN	B-PP	O		1228	1230
gastric	gastric	JJ	B-NP	O		1231	1238
cancer	cancer	NN	I-NP	O		1239	1245
in	in	IN	B-PP	O		1246	1248
young	young	JJ	B-NP	O		1249	1254
Japanese	Japanese	JJ	I-NP	O		1255	1263
people	people	NNS	I-NP	O		1264	1270
,	,	,	O	O		1270	1271
There	There	EX	B-NP	O		1272	1277
is	be	VBZ	B-VP	O		1278	1280
no	no	DT	B-NP	O		1281	1283
answer	answer	NN	I-NP	O		1284	1290
to	to	TO	B-PP	O		1291	1293
whether	whether	IN	B-SBAR	O		1294	1301
curing	cure	VBG	B-VP	O		1302	1308
H. pylori	H._pylori	NNP	B-NP	O		1309	1318
infection	infection	NN	I-NP	O		1319	1328
can	can	MD	B-VP	O		1329	1332
reverse	reverse	VB	I-VP	O		1333	1340
the	the	DT	B-NP	O		1341	1344
atrophy	atrophy	NN	I-NP	O		1345	1352
of	of	IN	B-PP	O		1353	1355
the	the	DT	B-NP	O		1356	1359
gastric	gastric	JJ	I-NP	O		1360	1367
mucosa	mucosa	NN	I-NP	O		1368	1374
and	and	CC	O	O		1375	1378
decrease	decrease	VB	B-VP	O		1379	1387
the	the	DT	B-NP	O		1388	1391
risk	risk	NN	I-NP	O		1392	1396
of	of	IN	B-PP	O		1397	1399
gastric	gastric	JJ	B-NP	O		1400	1407
cancer	cancer	NN	I-NP	O		1408	1414
development	development	NN	I-NP	O		1415	1426
.	.	.	O	O		1426	1427

To	To	TO	B-VP	O		1428	1430
clarify	clarify	VB	I-VP	O		1431	1438
this	this	DT	B-NP	O		1439	1443
issue	issue	NN	I-NP	O		1444	1449
,	,	,	O	O		1449	1450
an	an	DT	B-NP	O		1451	1453
intervention	intervention	NN	I-NP	O		1454	1466
study	study	NN	I-NP	O		1467	1472
must	must	MD	B-VP	O		1473	1477
be	be	VB	I-VP	O		1478	1480
done	do	VBN	I-VP	O		1481	1485
.	.	.	O	O		1485	1486

A	A	DT	B-NP	O		1487	1488
large	large	JJ	I-NP	O		1489	1494
clinical	clinical	JJ	I-NP	O		1495	1503
trial	trial	NN	I-NP	O		1504	1509
called	call	VBN	B-VP	O		1510	1516
the	the	DT	B-NP	O		1517	1520
Japanese	Japanese	NNP	I-NP	O		1521	1529
Intervention	Intervention	NNP	I-NP	O		1530	1542
Trial	Trial	NNP	I-NP	O		1543	1548
of	of	IN	B-PP	O		1549	1551
H. pylori	H._pylori	NNP	B-NP	O		1552	1561
is	be	VBZ	B-VP	O		1562	1564
in	in	IN	B-PP	O		1565	1567
progress	progress	NN	B-NP	O		1568	1576
.	.	.	O	O		1576	1577

